Pre-Diabetes Discovery Marks Step Towards Precision Medicine
Researchers from the University of Sydney’s Charles Perkins Centre have identified three specific molecules that accurately indicate insulin resistance, or pre-diabetes – a major predictor of metabolic syndrome, the collection of medical conditions that include abdominal obesity, high blood pressure and high blood sugar levels.
The finding, from a study undertaken in mice, could make earlier detection of pre-diabetes in humans much easier for doctors and allow for more personalised and effective treatments for patients in the future.
Researchers combined the high-tech mathematical approach of machine learning with omics technology that examines the various types of molecules that make up the cells of an organism to successfully identify specific molecules in mice. That information was used to classify the mice according to what kind of food they eat, their genetic origin and their whole-body insulin sensitivity.
Published in the Journal of Biological Chemistry, the research was conducted with the Garvan Institute of Medical Research, Duke University (USA) and the University of Melbourne.
Co-lead author Dr Jacqueline Stöckli, a research fellow with the University’s Charles Perkins Centre and School of Life and Environmental Sciences, said the study suggested there are likely multiple factors that contribute to pre-diabetes and this is why more traditional approaches have failed to identify similar highly predictive signatures or indicators of disease.
“Our study identified a three molecule signature that was able to diagnose insulin resistance or pre-diabetes, a condition that is often associated with diabetes, obesity and high blood pressure,” she said.
“But we know the story is much more complicated; strikingly, each of the three molecules on their own was considerably less predictive of pre-diabetes than when combined.
“The next step is to further exploit these technologies to uncover the full suite of pathways and factors that contribute to pre-diabetes – which will include genetic, environmental and possibly epigenetic influences – at a population level.”
The study represented a segue into precision medicine for humans, said senior author Professor David James, Leonard P. Ullmann Chair of Metabolic Systems Biology at the Charles Perkins Centre.
Precision medicine classifies individuals according to their susceptibility or response to a particular disease, and tailors healthcare treatments and practices accordingly.
“Once we can identify the molecules and other factors that contribute to pre-diabetes, we can customise treatments to suit patients’ specific make up and needs,” Professor James said.
“This study demonstrates the power of combining technologies to solve some of the world’s biggest problems,” he added.
“The burden of the ‘lifestyle diseases’ the Charles Perkins Centre is dedicated to easing – which include obesity, diabetes and cardiovascular disease – stubbornly remain at high levels globally; we need to innovate in order to tackle these conditions effectively.”
This article has been republished from materials provided by University of Sydney. Note: material may have been edited for length and content. For further information, please contact the cited source.
Jacqueline Stöckli, Kelsey H. Fisher-Wellman, Rima Chaudhuri, Xiao-Yi Zeng, Daniel J. Fazakerley, Christopher C. Meoli, Kristen C. Thomas, Nolan J. Hoffman, Salvatore P. Mangiafico, Chrysovalantou E. Xirouchaki, Chieh-Hsin Yang, Olga Ilkayeva, Kari Wong, Gregory J. Cooney, Sofianos Andrikopoulos, Deborah M. Muoio, David E. James. Metabolomic analysis of insulin resistance across different mouse strains and diets. Journal of Biological Chemistry, 2017; jbc.M117.818351 DOI: 10.1074/jbc.M117.818351.
Rapid Removal of Arsenic From Drinking Water...By Moss!News
A moss capable of removing arsenic from contaminated water has been discovered by researchers. And it happens quickly – in just one hour, the arsenic level is so low that the water is no longer harmful for people to drink.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018